InMode Ltd. INMD

Company Overview

InMode Ltd. is a medical technology company that develops, manufactures, and markets minimally invasive and non-invasive aesthetic medical products based primarily on radio-frequency (RF) technology. The company operates within the global medical aesthetics industry, serving physicians, dermatologists, plastic surgeons, gynecologists, and other healthcare practitioners. InMode’s systems are designed for procedures including facial contouring, skin rejuvenation, body contouring, women’s health treatments, and hair removal. Its primary revenue drivers include the sale of capital equipment platforms and recurring sales of consumables and service-related offerings.

The company was founded in Israel in 2008 by industry veterans with backgrounds in aesthetic energy-based devices, including Moshe Mizrahy and Dr. Michael Kreindel. InMode expanded rapidly through the commercialization of proprietary RF-assisted technologies intended to provide less invasive alternatives to traditional cosmetic surgery procedures. Since its Nasdaq listing in 2019, the company has positioned itself as a premium provider of clinically differentiated aesthetic platforms with a strong profitability profile relative to many peers in the medical aesthetics sector.

Business Operations

InMode generates revenue primarily through direct sales of aesthetic and wellness treatment platforms, as well as recurring sales from disposable consumables and service contracts. The company organizes its offerings around minimally invasive and non-invasive RF technologies marketed under product families such as BodyTite, FaceTite, Morpheus8, Evolve, EmpowerRF, and Optimas. These systems are used across applications including adipose tissue remodeling, skin tightening, fractional skin treatment, and women’s health therapies. A significant portion of revenue historically has come from North America, although the company maintains expanding international distribution operations.

The company operates through subsidiaries and distribution networks across multiple regions, including the United States, Europe, Asia-Pacific, and Latin America. InMode maintains vertically integrated research, development, manufacturing, and commercialization capabilities, with much of its engineering and manufacturing centered in Israel. The company’s business model emphasizes proprietary RF technology, physician training, and recurring procedural utilization. Public filings and investor materials indicate that InMode relies primarily on organic product development rather than large-scale joint ventures, although it works with distributors and clinical practitioners globally to expand adoption.

Strategic Position & Investments

InMode’s strategic direction has focused on expanding its portfolio of minimally invasive aesthetic and wellness technologies while increasing procedural adoption among physicians. The company has invested heavily in RF-assisted lipolysis, fractional RF skin resurfacing, and women’s health applications, areas viewed as growth segments within the broader medical aesthetics market. Management has consistently emphasized profitability, cash generation, and disciplined operational spending in contrast to more acquisition-driven competitors.

The company has also pursued selective acquisitions and intellectual property expansion to strengthen its technology base. Notable transactions include the acquisition of Invasix Ltd., which contributed foundational RF-assisted lipolysis technology to the business. InMode continues to invest in product innovation and software-enabled platform upgrades intended to increase treatment versatility and recurring consumable usage. Industry reports and company filings indicate that the company sees opportunities in non-invasive body contouring, regenerative aesthetics, and office-based wellness procedures, though market adoption rates can vary by geography and economic conditions.

Geographic Footprint

InMode is headquartered in Yokneam, Israel, with substantial commercial operations in the United States, which represents its largest market. The company maintains offices, distribution infrastructure, and sales operations across North America, Europe, Asia-Pacific, and parts of Latin America. Its international strategy includes both direct sales organizations and third-party distribution relationships depending on the market.

The company’s products are marketed in dozens of countries and are subject to regulatory approvals from agencies including the U.S. Food and Drug Administration and European regulatory authorities. InMode’s international presence has expanded alongside broader global demand for minimally invasive aesthetic procedures. Public disclosures indicate that fluctuations in foreign currency, regional economic conditions, and healthcare regulatory frameworks can influence operating performance across different geographies.

Leadership & Governance

InMode’s leadership team is composed largely of executives with longstanding experience in medical devices, energy-based aesthetic technologies, and healthcare commercialization. The company’s governance approach has emphasized technological innovation, operational efficiency, and sustained profitability. Leadership communications in public filings and earnings materials frequently stress physician education, product differentiation, and disciplined capital allocation as core strategic priorities.

Key executives include:

• Moshe Mizrahy – Chief Executive Officer
• Dr. Michael Kreindel – Chief Technology Officer
• Yair Malka – Chief Financial Officer
• Moti Kahana – President
• Marilyn Kelman – Chief Human Resources Officer

Information above is consistent with disclosures in SEC filings, company investor relations materials, and major financial market reporting sources reviewed as of 2026. Where executive roles or operational details may change over time, the most recent publicly filed company disclosures should be considered authoritative.